Providing for consideration of the bill (H.R. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.R. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes; and for other purposes.

Bill 115 H.Res. 787 is a resolution that sets the rules for considering two bills in the US Congress. The first bill, H.R. 4566, aims to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act. Specifically, it seeks to provide relief to nonbanks from certain stress test requirements under the Dodd-Frank Act. This bill is intended to ease regulatory burdens on nonbank financial institutions.

The second bill, H.R. 5247, focuses on authorizing the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition where death is likely to occur within a matter of months, or with another eligible illness. This bill aims to give patients access to potentially life-saving treatments that are still in the investigational stage.

Overall, Bill 115 H.Res. 787 sets the stage for the consideration of these two bills in Congress. The resolution outlines the procedures and rules that will govern the debate and voting process for H.R. 4566 and H.R. 5247. It is important to note that this summary provides a factual overview of the bill and does not take a stance on the content or implications of the legislation.